Cancer-testis antigen peptide-major histocompatibility complexes (MAGE-A1, MAGE-A3, NY-ESO-1) (CTA-pMHC)

MAGE-A1, MAGE-A3, and NY-ESO-1 are members of the cancer-testis antigen (CTA) family, which are proteins typically expressed only in the germ cells of the testis or placenta (UniProt P43355, P43357, P78358). Because these normal tissues do not express Major Histocompatibility Complex (MHC) Class I molecules, the antigens are not presented to the immune system under physiological conditions. However, in various malignancies, these genes are aberrantly de-repressed, leading to the presentation of specific peptide fragments on the cell surface via MHC molecules, primarily HLA-A*02:01 (PubMed: 23625181). This unique expression pattern makes these peptide-MHC complexes highly attractive targets for T-cell receptor (TCR) based therapies, as they provide a clear distinction between tumor cells and healthy somatic tissues (PubMed: 25406351). Therapeutic strategies include TCR-engineered T-cells (TCR-T) and bispecific T-cell engagers designed to recognize the specific peptide-HLA complex with high affinity. Clinical development has focused on solid tumors such as synovial sarcoma, melanoma, and non-small cell lung cancer, where high expression of these antigens correlates with poor prognosis (PubMed: 30224310). A critical safety consideration is the potential for off-target toxicity, exemplified by historical trials where TCR cross-reactivity with the cardiac protein Titin led to severe adverse events (Blood: 122(8)).

Other names

CTA-pMHCMAGE/NY-ESO-1 HLA complexesCancer-testis antigensMAGE-A1-HLA complexMAGE-A3-HLA complexNY-ESO-1-HLA complex

T-cell receptor (TCR) engineered T-cell therapy targeting specific peptide-MHC complexes to induce T-cell mediated lysis of tumor cells.